For a patient with hospital-acquired pneumonia requiring ventilatory support, which empiric regimen is appropriate?

• A. Cefepime, levofloxacin, and vancomycin
• B. Ceftriaxone and azithromycin
• C. Piperacillin-tazobactam and linezolid
• D. Piperacillin-tazobactam, amoxicillin, and vancomycin

Answer: (A)

The essential idea is that hospital-acquired pneumonia in a patient on ventilatory support requires broad, multi-drug coverage to address MDR pathogens. You want coverage for Pseudomonas and other Gram-negatives, plus MRSA, since these organisms are common and more likely in the ICU.

Cefepime provides strong anti-pseudomonal beta-lactam activity, limiting Gram-negative coverage gaps. Adding levofloxacin gives another mechanism active against Pseudomonas and broad Gram-negative coverage, so you have two anti-pseudomonal agents from different classes. Vancomycin supplies MRSA coverage, which is important in severe HAP/VAP where MRSA risk is present or high.

In contrast, regimens that lack robust anti-pseudomonal coverage (for example, those not targeting Pseudomonas) or that rely on only one anti-pseudomonal agent may fail to control MDR pathogens in this setting. Amoxicillin-containing regimens are not reliable for hospital pathogens in this context, and regimens that don’t include MRSA coverage risk missing MRSA infections.

After cultures and sensitivities return, you should narrow therapy to the most specific, effective agents.